Cardiff Oncology, Inc.

CRDF

Cardiff Oncology, Inc.

CRDF

Insider Sentiment (TTM):

Last Purchase:2026-06-18Last Sale:-Shares Purchased (TTM):54,703Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:24,358,432Shares Outstanding:68,350,000Institutional Ownership Pct.:35.64%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	9	9	17	10	11	24	51	13	26	19	22	15
Short Term Investments	25	38	41	50	60	56	40	45	35	49	53	66
Accounts Receivable Net Current	0	0	0	0	1	0	1	1	0	0	0	0
Prepaid Expense Current	1	1	2	1	2	2	3	1	1	2	2	2
Assets Current	36	47	60	62	74	83	95	59	62	70	77	84
Property Plant And Equipment Net	0	0	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	0	0	1	1	1	1	1	1	1	2	2	2
Other Assets Noncurrent	1	1	1	1	0	0	0	1	1	1	1	1
Assets	37	49	62	64	76	85	97	63	66	74	82	88
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	5	8	2	6	4	5	5	5	5	2	2
Accrued Liabilities Current	6	8	8	12	10	9	8	7	7	6	8	6
Operating Lease Liability Current	0	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	11	14	16	15	17	13	13	13	13	12	10	9
Operating Lease Liability Noncurrent	0	0	0	0	0	1	1	1	1	1	1	2
Liabilities	11	14	16	15	17	14	14	14	14	13	12	11
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	478	477	475	472	470	468	467	422	413	410	409	408
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-452	-442	-430	-423	-412	-398	-384	-372	-361	-349	-340	-330
Stockholders Equity	27	35	45	49	59	71	83	49	52	61	70	78
Liabilities And Stockholders Equity	37	49	62	64	76	85	97	63	66	74	82	88
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-	-	-	0.001	-
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	20	20
Temporary Equity Shares Authorized	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Liquidation Preference Value	1	1	1	1	1	1	1	1	1	1	1	1
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	69	68	68	67	67	67	67	49	46	45	45	45
Shares Outstanding	69	68	68	67	67	67	67	49	46	45	45	45

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-13.29%	-26.59%	-50.87%	-	-	-	-	-	-	-	-	-
2025	29.66%	19.77%	50.95%	-29.91%	-38.07%	-33.84%	1.33%	40.89%	28.89%	5.88%	5.88%	-1.76%
2024	-23.21%	-45.31%	-49.78%	8.45%	30.05%	32.86%	-36.19%	5.62%	-16.63%	-7.64%	-29.80%	-30.79%
2023	-	-	-	-	-	-	7.02%	28.95%	32.46%	230.51%	145.76%	105.08%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.30	3.27	3.67	4.20	4.42	6.22	7.08	4.74	4.97	5.91	7.41	9.30
Quick Ratio	3.21	3.20	3.57	4.14	4.29	6.04	6.89	4.65	4.85	5.71	7.19	9.04
Working Capital	24.80M	32.88M	43.73M	47.10M	57.03M	69.42M	81.63M	46.81M	49.72M	58.15M	66.97M	74.89M
Leverage & Debt
Debt to Equity	0.41	0.42	0.36	0.31	0.29	0.20	0.17	0.27	0.26	0.22	0.17	0.14
Debt Ratio	0.29	0.29	0.27	0.24	0.23	0.16	0.15	0.21	0.21	0.18	0.15	0.12
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00
Days Sales Outstanding TTM	256.87	207.18	293.91	318.28	327.16	248.10	283.50	216.14	167.95	319.82	396.04	336.43
Receivables Turnover TTM	1.42	1.76	1.24	1.15	1.12	1.47	1.29	1.69	2.17	1.14	0.92	1.08
Per Share Metrics
Diluted EPS TTM	-0.59	-0.65	-0.69	-0.75	-0.77	-0.73	-0.95	-0.92	-0.91	-0.90	-0.93	-0.91
Free Cash Flow Per Share TTM	-0.60	-0.55	-0.57	-0.44	-0.44	-0.64	-0.79	-0.74	-0.73	-0.69	-0.70	-0.76
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-8,320.08%	-9,033.90%	-8,256.32%	-10,741.00%	-9,969.17%	-8,875.64%	-7,123.13%	-6,735.99%	-6,711.28%	-7,261.15%	-9,305.74%	-9,667.83%
Net Profit Margin TTM	-7,885.24%	-8,526.10%	-7,732.04%	-10,089.20%	-9,364.59%	-8,325.72%	-6,655.20%	-6,238.17%	-6,143.91%	-6,594.92%	-8,492.01%	-8,868.48%
Growth Metrics
Net Revenue Growth (1Y)	-6.79%	-10.56%	-13.18%	-27.43%	-18.05%	-3.77%	39.96%	49.78%	61.41%	54.43%	26.42%	17.65%
Net Income Growth (1Y)	-21.51%	-8.41%	0.87%	17.37%	24.92%	21.48%	9.69%	5.36%	3.08%	3.33%	7.07%	3.35%
EPS Growth (1Y)	-23.66%	-10.86%	-28.09%	-17.76%	-15.83%	-18.41%	2.84%	0.44%	2.74%	3.32%	4.49%	0.24%
Valuation Metrics
P/E TTM	-2.22	-2.47	-4.10	-2.73	-4.11	-4.27	-4.55	-2.91	-2.44	-5.93	-1.60	-1.52
P/B TTM	3.35	3.19	4.14	2.82	3.58	2.95	2.49	2.53	1.90	3.92	0.95	0.80
P/S TTM	175.03	210.91	316.73	275.54	384.51	355.85	302.78	181.61	149.64	391.12	135.50	135.00
Market Cap	88.92M	110.73M	187.82M	137.77M	209.56M	208.89M	206.80M	125.13M	99.51M	238.58M	66.12M	62.10M
Enterprise Value	79.72M	102.18M	170.35M	127.64M	198.77M	184.79M	212.53M	112.09M	74.01M	219.92M	44.47M	46.87M
Calculated Values
Free Cash Flow TTM	-41.38M	-37.46M	-37.97M	-29.47M	-29.08M	-42.83M	-37.85M	-34.73M	-32.55M	-30.62M	-31.47M	-33.79M
Net Debt	-9.20M	-8.54M	-17.47M	-10.14M	-10.78M	-24.10M	5.73M	-13.04M	-25.50M	-18.66M	-21.66M	-15.23M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-18Purchase

Owner: Pace, Gary W

Title: -

Shares: 30,000

Price/Share: $1.22

Value: $36,600.00

Shares Owned: 1,356,376

Relationship: Director

Ownership: Direct

2026-06-18Purchase

Owner: Mohindru, Mani

Title: Chief Executive Officer

Shares: 24,703

Price/Share: $1.21

Value: $29,890.63

Shares Owned: 24,703

Relationship: Director,Officer

Ownership: Direct

2025-07-30Purchase

Owner: Pace, Gary W

Title: -

Shares: 275,000

Price/Share: $2.45

Value: $673,750.00

Shares Owned: 1,330,676

Relationship: Director

Ownership: Direct

2024-12-18Purchase

Owner: Levine, James E.

Title: Chief Financial Officer

Shares: 2,400

Price/Share: $5.00

Value: $12,000.00

Shares Owned: 67,716

Relationship: Officer

Ownership: Indirect

2024-12-12Purchase

Owner: Tannenbaum, Renee P

Title: -

Shares: 10,000

Price/Share: $3.42

Value: $34,200.00

Shares Owned: 20,000

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-18	Pace, Gary W	Director	-	Direct	Purchase	30,000	1.22	$36,600.00	1,356,376	4
2026-06-18	Mohindru, Mani	Director,Officer	Chief Executive Officer	Direct	Purchase	24,703	1.21	$29,890.63	24,703	4
2025-07-30	Pace, Gary W	Director	-	Direct	Purchase	275,000	2.45	$673,750.00	1,330,676	4
2024-12-18	Levine, James E.	Officer	Chief Financial Officer	Indirect	Purchase	2,400	5.00	$12,000.00	67,716	4
2024-12-12	Tannenbaum, Renee P	Director	-	Direct	Purchase	10,000	3.42	$34,200.00	20,000	4
2024-12-11	Pace, Gary W	Director	-	Direct	Purchase	350,115	2.60	$910,299.00	1,047,876	4
2023-12-19	Pace, Gary W	Director	-	Direct	Purchase	30,000	1.37	$41,100.00	697,761	4
2023-11-10	Pace, Gary W	Director	-	Direct	Purchase	22,950	0.98	$22,491.00	667,761	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

35.64%

Inst. Shares: 24,358,432

Shares Outstanding: 68,350,000

2025-12-31

40.46%

Inst. Shares: 27,043,359

Shares Outstanding: 66,841,000

2025-09-30

37.50%

Inst. Shares: 25,082,482

Shares Outstanding: 66,879,000

2025-06-30

42.48%

Inst. Shares: 28,257,205

Shares Outstanding: 66,526,000

2025-03-31

47.54%

Inst. Shares: 31,623,119

Shares Outstanding: 66,524,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	24,358,432	68,350,000	35.64%
2025-12-31	27,043,359	66,841,000	40.46%
2025-09-30	25,082,482	66,879,000	37.50%
2025-06-30	28,257,205	66,526,000	42.48%
2025-03-31	31,623,119	66,524,000	47.54%
2024-12-31	27,441,282	47,650,000	57.59%
2024-09-30	12,101,693	46,865,000	25.82%
2024-06-30	12,533,944	44,825,000	27.96%
2024-03-31	8,132,222	44,678,000	18.20%
2023-12-31	5,054,757	44,677,000	11.31%
2023-09-30	5,179,517	44,677,000	11.59%
2023-06-30	5,301,219	44,677,000	11.87%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cardiff Oncology, Inc. (CRDF) — SEC Financial Statements & Analysis

Cardiff Oncology, Inc. (CRDF) is a biological products, (no diagnostic substances) company, incorporated in DE. Cardiff Oncology, Inc. trades on Nasdaq as: CRDF. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Cardiff Oncology, Inc. reported a -6.79% year-over-year revenue growth, a Debt-to-Equity ratio of 0.41x, a Price-to-Sales (P/S) ratio of 175.03x (TTM), a Price-to-Book (P/B) ratio of 3.35x (TTM), at a market cap of $88.92M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -6.79%
Debt To Equity: 0.41x
P/S TTM: 175.03x
P/B TTM: 3.35x
Market Cap: $88.92M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cardiff Oncology, Inc. in?

Cardiff Oncology, Inc. (CRDF) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CRDF's market cap?

Cardiff Oncology, Inc. (CRDF) has a market capitalization of $88.92M as of 2026-06-30.

What exchange does CRDF trade on?

Cardiff Oncology, Inc. (CRDF) trades on the Nasdaq.

Where is Cardiff Oncology, Inc. incorporated?

Cardiff Oncology, Inc. is incorporated in DE.